Search

Your search keyword '"Kumada, Hiromitsu"' showing total 1,010 results
Start Over Author "Kumada, Hiromitsu" Search Limiters Academic (Peer-Reviewed) Journals
1,010 results on '"Kumada, Hiromitsu"'

3. Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma

Author

Kawamura, Yusuke, Akuta, Norio, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Tominaga, Licht, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Kozuka, Takuyo, and Kumada, Hiromitsu

Published
2023
Full Text
View/download PDF

4. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

8. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy

Author

Yuen, Man-Fung, Heo, Jeong, Kumada, Hiromitsu, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Xie, Qing, Jia, Jidong, Karino, Yoshiyasu, Hou, Jinlin, Chayama, Kazuaki, Imamura, Michio, Lao-Tan, Judy Y., Lim, Seng Gee, Tanaka, Yasuhito, Xie, Wen, Yoon, Jung-Hwan, Duan, Zhongping, Kurosaki, Masayuki, Park, Sung-Jae, Labio, Madalinee Eternity, Kumar, Rajneesh, Kweon, Young-Oh, Yim, Hyung Joon, Tao, Yu, Cremer, Jennifer, Elston, Robert, Davies, Matt, Baptiste-Brown, Sharon, Han, Kelong, Campbell, Fiona M., Paff, Melanie, and Theodore, Dickens

Published
2022
Full Text
View/download PDF

9. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.

Author

Kudo, Masatoshi, Finn, Richard S., Ikeda, Masafumi, Sung, Max W., Baron, Ari D., Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Meyer, Tim, Nagao, Satoshi, Saito, Kenichi, Mody, Kalgi, Ramji, Zahra, Dubrovsky, Leonid, and Llovet, Josep M.

Subjects
PROGRESSION-free survival, OVERALL survival, HEPATOCELLULAR carcinoma, PATIENT safety, ANTINEOPLASTIC agents
Abstract

Introduction: Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. Methods: 100 patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS), investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by the best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). Results: ORR was 43.0% (95% CI 33.1–53.3%) and median DOR was 17.1 months (95% CI 6.9–19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4–9.8 months) and 20.4 months (95% CI 14.4–25.9 months), respectively. No treatment-emergent ADAs were detected. Conclusion: Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis

Author

Fujiwara, Naoto, Kobayashi, Masahiro, Fobar, Austin J., Hoshida, Ayaka, Marquez, Cesia A., Koneru, Bhuvaneswari, Panda, Gayatri, Taguri, Masataka, Qian, Tongqi, Raman, Indu, Li, Quan-Zhen, Hoshida, Hiroki, Sezaki, Hitomi, Kumada, Hiromitsu, Tateishi, Ryosuke, Yokoo, Takeshi, Yopp, Adam C., Chung, Raymond T., Fuchs, Bryan C., Baumert, Thomas F., Marrero, Jorge A., Parikh, Neehar D., Zhu, Shijia, Singal, Amit G., and Hoshida, Yujin

Published
2021
Full Text
View/download PDF

12. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

Author

Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

13. An encapsulated bulky abdominal abscess due to amoeba

Author

Iritani, Soichi, Kawamura, Yusuke, Yamashige, Daiki, Muraishi, Nozomu, Kajiwara, Akira, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

14. A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report.

Author

Kawamura, Yusuke, Akuta, Norio, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, and Kumada, Hiromitsu

Subjects
IMAGE recognition (Computer vision), CELIAC artery, RADIAL artery, SUBCLAVIAN artery, MESENTERIC artery, TELERADIOLOGY, INTERVENTIONAL radiology
Abstract

Aim: The aim of this study was to evaluate the use of a new classification for safer transradial access hepatic interventional radiology, based on preoperative evaluation of the location of the left subclavian artery bifurcation in the aortic arch. Methods: A total of 38 consecutive patients with hepatocellular carcinoma and 74 sessions of radial access for visceral intervention (R.A.V.I.) were reviewed. We classified the location of the left subclavian artery bifurcation in the aortic arch in three areas using an oblique view computed tomography image matched with the curve of the aortic arches according to a new criteria Three Areas Criteria For R.A.V.I. (named "TAC‐F‐R"), and measured the required time from initial left radial artery arteriography to celiac artery or superior mesenteric artery arteriography. Results: The median time required for left radial artery arteriography to the celiac artery or superior mesenteric artery arteriography in each of the three areas were: area A, 0:11:10 (h, min, s); area B, 0:14:44; and area C, 0:31:51. There were significant differences between each area after Bonferroni correction (p < 0.01; A vs. B, p = 0.086; A vs. C, p = 0.001; and B vs. C, p = 0.045), with areas A and B requiring a significantly shorter time. Finally, no patients showed neurogenic disfunction within 1 week after the R.A.V.I. procedure. Conclusions: The new classification, "TAC‐F‐R," for safer transradial access hepatic interventional radiology is effective for avoiding difficult cases, and selects more suitable patients with hepatocellular carcinoma for the R.A.V.I. procedure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication

Author

Miki, Daiki, Akita, Tomoyuki, Kurisu, Akemi, Kawaoka, Tomokazu, Nakajima, Tomoaki, Hige, Shuhei, Karino, Yoshiyasu, Toyoda, Hidenori, Kumada, Takashi, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Aikata, Hiroshi, Hayes, Clair Nelson, Honda, Koichi, Seike, Masataka, Akuta, Norio, Kobayashi, Mariko, Kumada, Hiromitsu, Tanaka, Junko, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

19. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

Author

Suzuki, Fumitaka, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Tanaka, Yasuhito, Kurosaki, Masayuki, Yatsuhashi, Hiroshi, Atarashi, Tomofumi, Atsukawa, Masanori, Watanabe, Tsunamasa, Enomoto, Masaru, Kudo, Masatoshi, Maeda, Naoto, Kohno, Hiroshi, Joko, Kouji, Michitaka, Kojiro, Miki, Koichiro, Takahashi, Kazuhiro, Ide, Tatsuya, Fujiyama, Shigetoshi, Kohno, Tomoko, Itoh, Hiroshi, Tsukamoto, Sakiyo, Suzuki, Yuko, Kawano, Yoshiaki, Sugiura, Wataru, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

21. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Author

Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, and Kumada, Hiromitsu

Published
2020
Full Text
View/download PDF

23. Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Author

Finn, Richard S., Kudo, Masatoshi, Merle, Philippe, Meyer, Tim, Qin, Shukui, Ikeda, Masafumi, Xu, Ruocai, Edeline, Julien, Ryoo, Baek-Yeol, Ren, Zhenggang, Cheng, Ann-Lii, Galle, Peter R., Kaneko, Shuichi, Kumada, Hiromitsu, Wang, Anran, Mody, Kalgi, Dubrovsky, Leonid, Siegel, Abby B., and Llovet, Josep M

Published
2024
Full Text
View/download PDF

24. Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease.

Author

Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, and Suzuki, Fumitaka

Subjects
GENETIC polymorphisms, LIVER diseases, DISEASE risk factors, LDL cholesterol, LIVER function tests
Abstract

Aims: The effects of genetic polymorphism on a personalized diet and exercise program for steatotic liver disease (SLD) are still unclear. Methods: Participants of this retrospective cohort study were 203 Japanese patients with SLD diagnosed by abdominal ultrasonography. All of them were introduced the personalized diet and exercise treatment. A diet of 25–30 kcal/kg multiplied by ideal body weight (BW) daily and aerobic and resistance exercise (exercise intensity of 4–5 metabolic equivalents daily, respectively) were performed for 6 days. Treatment efficacy was evaluated in terms of the rate of decrease of liver function tests, glycolipid metabolism markers, physical findings, image findings, and cardiovascular disease (CVD) risk score at 6 months compared with baseline. Furthermore, the impact of genetic polymorphism was also investigated. Results: At 6 months compared with baseline, liver function tests (AST, ALT, γGTP), glycolipid metabolism markers (hemoglobin A1c, triglycerides [TG], low‐density lipoprotein cholesterol), physical findings (BW, body mass index), image finding (liver stiffness measurement), and CVD risk score (Suita score) improved significantly. There was no significant difference in treatment efficacy, except for the rates of decrease of TG, according to genotype PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs6834314. The rates of decrease of TG with TM6SF2 CT were significantly higher than those with CC or TT, and the rates of TG with HSD17B13 AA were significantly higher than those with AG by multiple comparisons. Conclusion: Personalized diet and exercise program for SLD improved liver function tests, physical findings, glycolipid metabolism markers, and CVD risk score. Genetic polymorphism might partially affect treatment efficacy. Further studies should be performed to develop an individualized program for SLD, considering genetic polymorphism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan

Author

Takaguchi, Koichi, Toyoda, Hidenori, Tsutsui, Akemi, Suzuki, Yoshiyuki, Nakamuta, Makoto, Imamura, Michio, Senoh, Tomonori, Nagano, Takuya, Tada, Toshifumi, Tachi, Yoshihiko, Hiraoka, Atsushi, Michitaka, Kojiro, Shibata, Hiroshi, Joko, Kouji, Okubo, Hironao, Tsuji, Kunihiko, Takaki, Shintaro, Watanabe, Tsunamasa, Ogawa, Chikara, Chayama, Kazuaki, Kumada, Takashi, Kudo, Masatoshi, and Kumada, Hiromitsu

Published
2019
Full Text
View/download PDF

30. Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study.

Author

Chayama, Kazuaki, Hiramatsu, Akira, Shima, Toshihide, Itoh, Yoshito, Yamaguchi, Kanji, Nakajima, Tomoaki, Hoshikawa, Kyoko, Kawamura, Yusuke, Akuta, Norio, Ito, Kiyoaki, Kawanaka, Miwa, Sakamoto, Michiie, Harada, Kenichi, Goto, Yoshihito, Nakayama, Takeo, Kumada, Hiromitsu, and Okanoue, Takeshi

Subjects
FATTY liver, NON-alcoholic fatty liver disease, JAPANESE people, BODY mass index, LIVER biopsy, SCIENTIFIC observation
Abstract

Aim: There are few reports on the prognosis of liver‐related events in Japanese patients with nonalcoholic fatty liver disease (NAFLD). We undertook an observational study to compare the prognosis between fibrotic and nonfibrotic groups in Japanese NAFLD patients. Methods: Prognosis in 393 NAFLD patients who underwent liver biopsy between April 2013 and April 2015 at multiple centers were investigated. The time to onset of liver‐related events, cardiovascular events, development of extrahepatic cancers, and death were compared between the pathologically fibrotic nonalcoholic steatohepatitis (NASH) group and nonalcoholic fatty liver (NAFL) + nonfibrotic NASH group. A similar analysis was carried out based on the fibrotic classification diagnosed using four noninvasive fibrosis prediction models. Results: The mean age and body mass index at the time of liver biopsy was 55.7 years old and 28.04 kg/m2, respectively The cumulative incidence of liver‐related events at 1080 days after liver biopsy was 5.79% in the pathologically fibrotic NASH group and 0% in the NAFL + nonfibrotic NASH group, with a significant difference (p = 0.0334). The cumulative incidence of liver‐related events was significantly higher in the positive group for the prediction model than in the negative group in all four models (all p values were <0.0001). There was no significant difference between the pathologically fibrotic NASH group and NAFL + nonfibrotic NASH group in terms of cumulative incidence of cardiovascular events, development of extrahepatic cancers, and death. Conclusions: The incidence of liver‐related events was significantly higher in the fibrotic NASH group than that of the NAFL + nonfibrotic NASH group in Japanese NAFLD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.

Author

Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Saitoh, Satoshi, Kobayashi, Mariko, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, and Suzuki, Fumitaka

Subjects
ALPHA fetoproteins, LIVER tumors, GENETIC mutation, TELOMERASE, MULTIVARIATE analysis, FATTY liver, FISHER exact test, MANN Whitney U Test, TREATMENT effectiveness, CHI-squared test, KAPLAN-Meier estimator, RESEARCH funding, PROGRESSION-free survival, ODDS ratio, LOGISTIC regression analysis, LONGITUDINAL method
Abstract

Introduction: Personalized medicine and molecular therapies with the diagnosis of somatic genetic alterations are expected to be developed for liver cancer. Nevertheless, it is unknown whether a mutation in the telomere reverse transcriptase promoter (TERT C228T) in serum cfDNA might be useful for making prognostic predictions after surgical resection for primary liver cancer. Methods: This cohort study retrospectively investigated 111 patients who had undergone surgical resection of liver cancer for the first time. We investigated the differences between clinicopathological features and prognosis according to classification of three tumor markers, including AFP, PIVKAII, and TERT C228T. Results: Multivariate analysis identified etiology (fatty liver disease vs. HBV odds ratio [OR] 6.853) and fibrosis stage (2–4, OR: 0.137) as determinants of TERT C228T-positive liver cancer with normal levels of AFP and PIVKAII (TERT single positive liver cancer). TERT single positive (Yes, OR: 0.301), fibrosis (FIB)-4 index (≥3.25, OR: 2.038), Child-Pugh classification (B, OR: 4.975), and number of tumors (≥2, OR: 4.098) were identified as determinants of the recurrence of liver cancer. TERT single positive (Yes, OR: 3.311), FIB-4 index (≥3.25, OR: 0.433), and number of tumors (≥2, OR: 0.262) were identified as determinants of disease-free survival. Conclusions: Our results highlight the impact of classification of prognostic tumor markers. TERT single positive is one predictor of favorable prognosis after surgical resection for liver cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection

Author

Akuta, Norio, Toyota, Joji, Karino, Yoshiyasu, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, McPhee, Fiona, Noviello, Stephanie, and Kumada, Hiromitsu

Published
2018
Full Text
View/download PDF

34. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Author

Kumada, Hiromitsu, Watanabe, Tsunamasa, Suzuki, Fumitaka, Ikeda, Kenji, Sato, Ken, Toyoda, Hidenori, Atsukawa, Masanori, Ido, Akio, Takaki, Akinobu, Enomoto, Nobuyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David, Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, and Chayama, Kazuaki

Published
2018
Full Text
View/download PDF

35. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Author

Chayama, Kazuaki, Suzuki, Fumitaka, Karino, Yoshiyasu, Kawakami, Yoshiiku, Sato, Ken, Atarashi, Tomofumi, Naganuma, Atsushi, Watanabe, Tsunamasa, Eguchi, Yuichiro, Yoshiji, Hitoshi, Seike, Masataka, Takei, Yoshiyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David L., Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, and Kumada, Hiromitsu

Published
2018
Full Text
View/download PDF

37. Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma.

Author

Kawamura, Yusuke, Akuta, Norio, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Tominaga, Licht, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Kozuka, Takuyo, and Kumada, Hiromitsu

Subjects
THERAPEUTIC use of monoclonal antibodies, DRUG efficacy, KRUSKAL-Wallis Test, CANCER chemotherapy, MULTIVARIATE analysis, LOG-rank test, ANTINEOPLASTIC agents, FISHER exact test, TUMOR classification, CANCER patients, PROTEIN-tyrosine kinase inhibitors, TREATMENT failure, RESEARCH funding, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, LACTATE dehydrogenase, KAPLAN-Meier estimator, BEVACIZUMAB, DATA analysis software, FRIEDMAN test (Statistics), DRUG side effects, HEPATOCELLULAR carcinoma, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: The Barcelona clinic liver cancer (BCLC) system is used widely for staging hepatocellular carcinomas (HCCs). However, it is questionable that for patients classified as BCLC stage C, control of intrahepatic targets using various treatment procedures is not the main topic of discussion, whereas the importance of intrahepatic tumor control in patients with extrahepatic tumor spread is reviewed. Therefore, this study analyzed the data of 64 consecutive BCLC stage C patients with intrahepatic target nodules who received systemic therapy and evaluated the efficacy of the combined use of systemic sequential therapy, including more than two agents, and locoregional treatment administered after initiation of systemic therapy. We showed that the combined use of systemic sequential therapy of more than two agents and locoregional-treatment improved overall survival in BCLC stage C HCC patients with intrahepatic target nodules who had previously received systemic therapy-based treatment. Background: The aim of this study was to evaluate the clinical impact of a combination of systemic sequential therapy and locoregional therapy on the long-term survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). Methods: Sixty-four consecutive patients with intrahepatic target nodules who had initially received systemic therapy (lenvatinib and atezolizumab plus bevacizumab) were reviewed. The clinical impact of the combined use of systemic sequential therapy and locoregional therapy was evaluated by determining overall survival (OS). The combined use of systemic sequential therapy with more than two agents and locoregional treatment was defined as multidisciplinary combination therapy (MCT), while only systemic sequential therapy and repeated locoregional-treatment was defined as a single treatment procedure (STP). Results: R0 resection, MCT, and STP resulted in significantly better OS compared with no additional treatment (median OS, not reached vs. 18.2 months and 12.6 vs. 8.1 months, respectively; p = 0.002). Multivariate analysis confirmed that the use of R0 resection and MCT were associated with better OS (hazard ratio [HR]; 0.053, p = 0.006 and 0.189, p < 0.001, respectively) compared with that for STP (HR; 0.279, p = 0.003). Conclusions: MCT is may effective in patients with BCLC stage C HCC and intrahepatic target nodules who have previously received systemic therapy-based treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors.

Author

Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, and Suzuki, Fumitaka

Subjects
FATTY liver, NON-alcoholic fatty liver disease, TREATMENT effectiveness, METABOLIC equivalent, RESISTANCE training, LIVER function tests
Abstract

Aims: Both diet and exercise counseling are recommended for patients with fatty liver, including nonalcoholic fatty liver disease (NAFLD), to achieve weight loss goals. However, data evaluating treatment efficacy are limited. Methods: The subjects of this retrospective cohort study were 186 consecutive Japanese cases with fatty liver diagnosed by abdominal ultrasonography. Treatment efficacy and predictive factors of "Hospitalization Program for Improvement Purpose for Fatty Liver" as a combined diet and aerobic and resistance exercise program were evaluated according to the hospitalization group (153 cases) or the no hospitalization group (33 cases). To balance the confounding biases, treatment efficacy was evaluated using propensity score‐matched analysis. In the hospitalization group, a diet of 25–30 kcal/kg multiplied by ideal body weight (BW) daily and aerobic and resistance exercise (exercise intensity of 4–5 metabolic equivalents daily, respectively) were performed for 6 days. Results: In liver function tests and BW at 6 months compared with baseline, the rates of decrease of the hospitalization group (24 cases) were significantly higher than those of the no hospitalization group (24 cases), using propensity score‐matched analysis. In markers of glycolipid metabolism and ferritin levels, the rates of the hospitalization group were not different from those of the no hospitalization group. In the hospitalization group (153 cases), multivariate regression analysis identified the etiology of non‐NAFLD, the presence of diabetes mellitus, and large waist circumference as independent predictors of decreased rates of hemoglobin A1c levels. Conclusion: The diet and exercise program for fatty liver improved liver function tests and BW. Further study should be performed to develop a feasible and suitable program. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

Author

Kumada, Hiromitsu, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Chayama, Kazuaki, Kawada, Norifumi, Okanoue, Takeshi, Itoh, Yoshito, Mochida, Satoshi, Toyoda, Hidenori, Yoshiji, Hitoshi, Takaki, Shintaro, Yatsuzuka, Naoyoshi, Yodoya, Etsuo, Iwasa, Takashi, Fujimoto, Go, Robertson, Michael N., Black, Stuart, Caro, Luzelena, and Wahl, Janice

Published
2017
Full Text
View/download PDF

45. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

Author

Toyota, Joji, Karino, Yoshiyasu, Suzuki, Fumitaka, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, Hu, Wenhua, McPhee, Fiona, Linaberry, Misti, Yin, Philip D., Swenson, Eugene Scott, and Kumada, Hiromitsu

Published
2017
Full Text
View/download PDF

48. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

Author

Toyoda, Hidenori, Chayama, Kazuaki, Suzuki, Fumitaka, Sato, Ken, Atarashi, Tomofumi, Watanabe, Tsunamasa, Atsukawa, Masanori, Naganuma, Atsushi, Notsumata, Kazuo, Osaki, Yukio, Nakamuta, Makoto, Takaguchi, Koichi, Saito, Satoru, Kato, Koji, Pugatch, David, Burroughs, Margaret, Redman, Rebecca, Alves, Katia, Pilot‐Matias, Tami J., Oberoi, Rajneet K., Fu, Bo, and Kumada, Hiromitsu

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results